These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33710417)

  • 1. Estimating copy number using next-generation sequencing to determine ERBB2 amplification status.
    Nakamura K; Aimono E; Oba J; Hayashi H; Tanishima S; Hayashida T; Chiyoda T; Kosaka T; Hishida T; Kawakubo H; Kitago M; Okabayashi K; Funakoshi T; Okita H; Ikeda S; Takaishi H; Nishihara H
    Med Oncol; 2021 Mar; 38(4):36. PubMed ID: 33710417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays.
    Robinson CL; Harrison BT; Ligon AH; Dong F; Maffeis V; Matulonis U; Nucci MR; Kolin DL
    Mod Pathol; 2021 Mar; 34(3):603-612. PubMed ID: 33077919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer.
    Xia D; Kuo F; Hughes M; Lindeman N; Manning D; Files J; Strauss S; Kirkner G; Mohammed-Abreu A; Winer E; Tolaney SM; Lin NU; Dillon DA
    Am J Clin Pathol; 2024 May; 161(5):436-442. PubMed ID: 38104247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.
    Christgen M; van Luttikhuizen JL; Raap M; Braubach P; Schmidt L; Jonigk D; Feuerhake F; Lehmann U; Schlegelberger B; Kreipe HH; Steinemann D
    Oncotarget; 2016 Dec; 7(50):82733-82740. PubMed ID: 27716627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
    Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
    Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer.
    Ichikawa H; Usui K; Aizawa M; Shimada Y; Muneoka Y; Kano Y; Sugai M; Moro K; Hirose Y; Miura K; Sakata J; Yabusaki H; Nakagawa S; Kawasaki T; Umezu H; Okuda S; Wakai T
    BMC Cancer; 2024 Jun; 24(1):719. PubMed ID: 38862927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing.
    Ferguson DC; Momeni Boroujeni A; Zheng T; Mohanty AS; Ho AL; Arcila ME; Ross DS; Dogan S
    Mod Pathol; 2022 Jul; 35(7):895-902. PubMed ID: 34963694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.
    Ross DS; Zehir A; Cheng DT; Benayed R; Nafa K; Hechtman JF; Janjigian YY; Weigelt B; Razavi P; Hyman DM; Baselga J; Berger MF; Ladanyi M; Arcila ME
    J Mol Diagn; 2017 Mar; 19(2):244-254. PubMed ID: 28027945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.
    Cenaj O; Ligon AH; Hornick JL; Sholl LM
    Am J Clin Pathol; 2019 Jun; 152(1):97-108. PubMed ID: 31115453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated genomic characterization of ERBB2/HER2 alterations in invasive breast carcinoma: a focus on unusual FISH groups.
    Yang SR; Bouhlal Y; De La Vega FM; Ballard M; Kuo CJ; Vilborg A; Jensen G; Allison K
    Mod Pathol; 2020 Aug; 33(8):1546-1556. PubMed ID: 32161378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.
    Pfarr N; Penzel R; Endris V; Lier C; Flechtenmacher C; Volckmar AL; Kirchner M; Budczies J; Leichsenring J; Herpel E; Noske A; Weichert W; Schneeweiss A; Schirmacher P; Sinn HP; Stenzinger A
    Genes Chromosomes Cancer; 2017 Apr; 56(4):255-265. PubMed ID: 27792260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
    Ni R; Mulligan AM; Have C; O'Malley FP
    Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number.
    Mrhalová M; Kodet R; Kalinová M; Hilská I
    Pathol Res Pract; 2003; 199(7):453-61. PubMed ID: 14521261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers.
    Niu D; Li L; Yu Y; Zang W; Li Z; Zhou L; Jia L; Rao G; Gao L; Cheng G; Ji K; Lin D
    Pathol Oncol Res; 2020 Oct; 26(4):2577-2585. PubMed ID: 32621174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers.
    Shah AN; Sunderraj A; Finkelman B; See SH; Davis AA; Gerratana L; Wehbe F; Katam N; Mahalingam D; Gradishar WJ; Behdad A; Blanco L; Cristofanilli M
    Oncotarget; 2022; 13():273-280. PubMed ID: 35126865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
    Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
    Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing: A Direct Comparison Study with Immunohistochemistry.
    Choi S; Chu J; Kim B; Ha SY; Kim ST; Lee J; Kang WK; Han H; Sohn I; Kim KM
    J Mol Diagn; 2019 Jul; 21(4):612-622. PubMed ID: 31022472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
    Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
    Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization Results.
    Geiersbach KB; Sill DR; Del Rosario KM; Meyer RG; Spears GM; Yuhas JA; Sukov WR; Jenkins RB; Ocal IT; Mounajjed T; Chen B
    Am J Clin Pathol; 2021 Oct; 156(5):886-894. PubMed ID: 33942843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.